Sang Nguyen is from Vietnam, a low- and middle-income country, and completed his medical training from Hanoi Medical University, the first ranked top medical university in Vietnam, in 2010. He worked as a physician scientist at Hanoi Medical University on HIV/AIDS related research before joining the Epidemiology Ph.D. Program at Vanderbilt University under the mentorship of Prof. Xiao-Ou Shu in August 2016. His first two years of graduate study between 2017 and 2018 was supported by the prestigious Vietnam Education Foundation (VEF) Fellowship funded by the U.S. Congress. Sang Nguyen’s research interest is cancer epidemiology with a focus on understanding biological mechanisms related to modifiable factors, which would lead to the development of personalized preventive strategies for improving cancer prognosis. In 2019, he was awarded the Vanderbilt-Emory-Cornell-Duke (VECD) Fogarty global health fellowship, which supported him to spend one year at Vietnam National Cancer institute (VNCI) between 2019 and 2020 to receive training in field epidemiology and collect information for his dissertation research. Sang Nguyen developed his Ph.D. dissertation project to assess the incidence of toxicities of chemotherapy among Vietnamese women with breast cancer and investigate influence of gut microbiome and lifestyle factors on chemotherapy related toxicity.

Dr. Wu is a Professor and medical director at the Peking University Cancer Hospital. He is board certified in thoracic surgery, and belongs to several professional societies including the International Association for the Study of Lung Cancer (IASLC), Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association, Beijing Association for Thoracic Surgery. He is currently serving as the deputy chair of membership committee of the IASLC, Vice president of Beijing Society of Clinical Oncology.
Dr. Wu also serves as vice director of the Multidisciplinary Thoracic Oncology Program at the Peking University Cancer Hospital, which provides service of clinical oncology and thoracic surgery for Chinese patients’ group covering central and north part of china. He is the principal investigators for several national-level and regional-level projects, involving biomarkers detection and mechanism of carcinogenesis and immune evasion of lung cancer.
Dr. Wu’s research interests focus on exploring the carcinogenesis and biomarkers of early stage lung cancer, improving the quality of surgical care and perioperative adjuvant treatments, collaborating with experts of artificial intelligence and developing applicable clinical decision supporting systems for diagnosis and treatment procedures of lung cancer. His research interests also cover the genetic mechanisms of rare thoracic tumors, such as esophageal melanoma.

Professor Mariano Provencio graduated in Medicine and Surgery in 1986 from the University Alcalá de Madrid,and gained his doctorate cum laude from the same university in 1997. He specialised as a resident physician in Medical Oncology in the Hospital Universitario Puerta de Hierro, in Madrid. His background was completed in 1995 when he was awarded the European Certificate in Medical Oncology in Paris. He later spent time at the Memorial Sloan-Kettering Cancer Center, New York in 2003, at MD Anderson, Houston in 2006 and 2012, and at the Lee Moffit Cancer Center, Tampa, in 2009. After finishing his residency, he joined the Medical Oncology Service in Puerta de Hierro Hospital in Madrid.
In 2011 he was appointed Head of the Medical Oncology Department in Puerta de Hierro University Hospital Majadahonda, Madrid, and became the Director of the Puerta de Hierro Research Institute. He is a Full Professor in the Autonomous University of Madrid.
He is the author of more 300 peer-reviewed papers and several books chapters. His publications have >18,000 citations (h-index of 56, i10-index of 164)
Since 2014, Professor Provencio has been President of the Spanish Lung Cancer Group